Pooled statistical meta-analyses and systematic reviews aggregating thousands of patients across multiple randomized controlled trials to measure true effect size. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
In the second meta-analysis, we compared patients with high weight (over 4000 g) and eczema with those with normal weight and eczema.
Sitagliptin is similar to metformin in reducing HbA1c, decreasing body weight, and improving the function of beta cells, but is inferior to metformin in improving insulin sensitivity.
This meta-analysis indicates that the effect of CPAP on cognition is small and limited to attention.
In daily practice, treatment of hypertensive patients with additional risk factors with amlodipine/valsartan single-pill combinations is well tolerated and associated with effective reduction of blood pressure.
All 5 domains of executive function demonstrated medium to very large impairments in OSA independent of age and disease severity.
Findings from this meta-analysis supported that moderate-severe OSA significantly increased heart and blood vessel risk, in particular stroke risk.
Vertex pattern AGA was associated with a significant increased risk of prostate cancer.
Current available published evidence is insufficient to support an increased risk of AP or cancer associated with GLP-1 agonists.
Metformin, but not sulfonylurea, appears to reduce subsequent cancer risk.
Considering the average BMI at baseline (32.4 kg/m(2)) these data means a weight reduction of about 3% at 6 months.
However, these meta-analyses included a number of studies with a limited follow-up period, thus impairing the possibility to make a proper comparison of the long-term effects of metformin.
The meta-analysis of the available cross-sectional data suggests that T2DM can be considered independently associated with male hypogonadism.
Lower testosterone and higher E(2) levels correlate with increased risk of CVD and CV mortality.
We could find no robust evidence supporting the superiority of candesartan over losartan in the treatment of heart failure.
Mild RI, as determined by the Cockcroft-Gault equation, had no effect on the real-world benefits and safety of liraglutide in this meta-analysis.
The critical literature appraisal and meta-analyses show that nasal surgery can effectively reduce daytime sleepiness and snoring.
The meta-analysis of the available cross-sectional data suggests that MetS can be considered an independent association of male hypogonadism.
To date, results of randomized trials do not suggest any detrimental effect of GLP-1 receptor agonists on heart and blood vessel events.
Incretin-based therapies are effective in blood sugar control and also offer other advantages such as weight loss (exenatide and liraglutide).
Test accuracy in repeated validation studies of the same screening test is variable, suggesting an underlying heterogeneity in either the clinical presentation of obstructive sleep apnea or the measured clinical elements of...
Metformin decreases the rate of conversion from prediabetes to diabetes.
Of studies that met inclusion criteria, none demonstrated that testosterone therapy for hypogonadism increased prostate cancer risk or increased Gleason grade of cancer detected in treated vs untreated men.
Percentages of change in GFR improved significantly with both treatments.
Tacrolimus ointment therapy resulted in the full symptom relief of eczema, this effect of tacrolimus ointment strengths 0.03% and 0.1% were better than those of 1% hydrocortisone acetate and 1% pimecrolimus.
1.25+/-1.09, p=0.569), or HAM-A scores at endpoint (3.30+/-2.89 vs.
In the long term metformin reduces the risks of clinical events associated with diabetes.
Metformin produces beneficial changes in glycaemia control, and moderated in weight, lipids, insulinaemia and diastolic blood pressure.
Statistically significant heterogeneity in the rate of recurrence was observed (P = .02; two-sided likelihood-ratio test) between the two studies, indicating that chance may not be the only explanation.
Basing on the evidence-based approach, the conclusion on efficacy of the following modern drugs in the treatment of erectile dysfunction are made: sildenafil, iochimbin, prostaglandin E1 and tadalafil.
Atorvastatin 10 mg, simvastatin 20 mg and pravastatin 20 mg; for HDL-C elevations, p <0.01 vs.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
